A pilot study on changes of macrophage colony stimulating factor and transforming growth factor 1 in male patients with ankylosing spondylitis taking thalidomide
| Autor: | L J Zhao, Ling Qin, M Ito, L M He, Pingting Yang, W G Xiao |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Macrophage colony-stimulating factor
medicine.medical_specialty Ankylosing spondylitis business.industry Immunology Diclofenac Sodium medicine.disease Gastroenterology General Biochemistry Genetics and Molecular Biology Surgery Thalidomide Rheumatology Internal medicine medicine Immunology and Allergy business Spondylitis BASDAI Progressive disease medicine.drug Antibacterial agent |
| Zdroj: | Annals of the Rheumatic Diseases. 69:781-782 |
| ISSN: | 0003-4967 |
| Popis: | Ankylosing spondylitis (AS) is a progressive disease of which spinal fusion is the clinical and pathological hallmark. Thalidomide has some efficacy in treating axial inflammation in AS.1 Here, we report clinical responses and changes of serum macrophage colony stimulating factor (M-CSF) and transforming growth factor β1 (TGFβ1) in Chinese male patients with active AS taking thalidomide. This study enrolled 29 male patients with active AS, whose Bath ankylosing spondylitis disease activity index (BASDAI) was 3 or above.2 A total of 16 patients not intending to have children within the next 2 years took thalidomide (75 mg every night postoperatively) and diclofenac sodium (50 mg 3 times a day postoperatively) for 12 weeks; other patients took diclofenac sodium (50 mg 3 times a day postoperatively) alone. There were no … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|